TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00509366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed & Gemcitabine
Description: Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed & Gemcitabine
Description: Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles
Study: NCT01250886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's solution
Description: Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution
Description: Normal saline solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetate Ringer's solution
Description: Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
Study: NCT03151291

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-hydroxy-β-methylbutyrate (HMB)
Description: daily intake of 3 g HMB

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-hydroxy-β-methylbutyrate (HMB)
Description: daily intake of 3 g HMB

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine (LC)
Description: daily intake of 4 g LC

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine (LC)
Description: daily intake of 4 g LC

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Description: daily intake of 2.2 g EPA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Description: daily intake of 2.2 g EPA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation (WB-EMS)
Description: WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation (WB-EMS)
Description: WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation (WB-EMS)
Description: WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation (WB-EMS)
Description: WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
Study: NCT01846910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tooth Whitening
Description: 1. A dental check-up will ensure the absence of contraindications to tooth whitening (cavities, soft tissue pathology, severe periodontitis) 2. Removal of calculus, plaque, or stains with a dental polishing 3. Treatment time is approximately 1 hour total4. Lips are retracted, tongue protector is placed and protective eyewear used 5. Saliva is suctioned and teeth are air dried 6. A liquid rubber dam material is applied to protect gums and cured by visible light. 7. The bleaching material is placed on the enamel surface of the involved teeth and is replaced if drying occurs 8. After 15 minutes, the bleach is suctioned, mouth rinsed and process repeated 9. Three to four applications are typically used

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Counseling
Description: Normally three counseling sessions. Session #1: Introductions; discuss habits, feelings, pros and cons of smoking; degree of addiction; previous quit attempts and relapse; reinforce patient confidence; open-ended questions to illicit self-efficacy; homework includes Pack-Track and Why Test. Session #2: Discuss smoking patterns, triggers, and risk situations; discuss methods to resist triggers, need for medications; prepare environment and back-up plan; discuss quit date; homework to review self-help workbook. Session #3: Reinforce previous concepts; review resistance plan; discuss and arrange pharmaceutical cessation aids; set quit date; homework to finalize all self/home preparations; offer tooth polishing on quit date; follow-up by telephone or appointment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Counseling
Description: Normally three counseling sessions. Session #1: Introductions; discuss habits, feelings, pros and cons of smoking; degree of addiction; previous quit attempts and relapse; reinforce patient confidence; open-ended questions to illicit self-efficacy; homework includes Pack-Track and Why Test. Session #2: Discuss smoking patterns, triggers, and risk situations; discuss methods to resist triggers, need for medications; prepare environment and back-up plan; discuss quit date; homework to review self-help workbook. Session #3: Reinforce previous concepts; review resistance plan; discuss and arrange pharmaceutical cessation aids; set quit date; homework to finalize all self/home preparations; offer tooth polishing on quit date; follow-up by telephone or appointment.
Study: NCT02183181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam tablet
Study: NCT00823108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIK
Description: 12 hour infusion of GIK solution
Study: NCT01746459

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper-Based Reminder System
Description: Paper-based reminders include: a) affixing stickers to clients' bedroom doors, beside their beds, or in their bathrooms; b) posting signs in prominent locations; and c) placing colored flags on the documentation flowsheets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper-Based Reminder System
Description: Paper-based reminders include: a) affixing stickers to clients' bedroom doors, beside their beds, or in their bathrooms; b) posting signs in prominent locations; and c) placing colored flags on the documentation flowsheets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper-Based Reminder System
Description: Paper-based reminders include: a) affixing stickers to clients' bedroom doors, beside their beds, or in their bathrooms; b) posting signs in prominent locations; and c) placing colored flags on the documentation flowsheets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper-Based Reminder System
Description: Paper-based reminders include: a) affixing stickers to clients' bedroom doors, beside their beds, or in their bathrooms; b) posting signs in prominent locations; and c) placing colored flags on the documentation flowsheets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peer-Based Reminder System
Description: Healthcare aides will provide formal and informal peer reminders about the mobility activity; the formal reminders will take place either monthly or every three months during change of shift meetings, while the informal reminders will be provided as opportunities arise during the work day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peer-Based Reminder System
Description: Healthcare aides will provide formal and informal peer reminders about the mobility activity; the formal reminders will take place either monthly or every three months during change of shift meetings, while the informal reminders will be provided as opportunities arise during the work day.
Study: NCT00785460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benfotiamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benfotiamine
Study: NCT03269318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast or Salmeterol or Theophylline or Steroid
Description: Medication will be patient specific according to their current medication, clinical symptoms and genotype. It will be from a choice of; leukotriene receptor antagonist (montelukast), long-acting beta2 agonist (salmeterol), theophylline or increase dose of inhaled steroid.
Study: NCT04541316

Intervention type: DEVICE
Intervention: ProFlor inguinal hernia device
Description: Inguinal hernia repair

Intervention type: DEVICE
Intervention: ProFlor inguinal hernia device
Description: Inguinal hernia repair
Study: NCT00439270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.
Study: NCT04541316

Intervention type: DEVICE
Intervention: ProFlor inguinal hernia device
Description: Inguinal hernia repair
Study: NCT04029753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk out from operating room
Description: After the surgery of laparoscopic radical gastrectomy, patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb.
Study: NCT00914953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin (Pitocin)
Description: 40 IU OT intranasally (IN) once-daily for 10 consecutive days
Study: NCT00824616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: MK-0941 tablets 5 mg or 10 mg, taken 3 times daily, with increasing doses to maximally effective dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, taken 3 times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin glargine (rDNA origin) injection solution for subcutaneous (SC) injection, taken once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Insulin glargine (rDNA origin) injection solution for subcutaneous (SC) injection, taken once daily.
Study: NCT02449096

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscope
Description: AORIF - arthroscopically assisted open reduction and internal fixation of acute ankle fractures

Intervention type: OTHER
Group type: OTHER
Intervention: No arthroscope
Description: ORIF - open reduction and internal fixation of acute ankle fractures
Study: NCT01468818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young Tumor Infiltrating Lymphocytes (TIL)
Description: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL. On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
Study: NCT01801631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visits
Description: In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Consultation by telephone
Description: In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
Study: NCT02336724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Study: NCT01004003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: Dose escalated in phase I until MTD or adjusted by investigator, dose in phase II part based on phase I data
Study: NCT02829151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )
Description: Combination antiplatelet therapy using aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) after the index angioplasty

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel
Description: Combination antiplatelet therapy using aspirin (100 mg) and clopidogrel (75 mg) after the index angioplasty

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol
Description: Combination antiplatelet therapy using aspirin (100 mg) and cilostazol (200 mg) after the index angioplasty
Study: NCT03097510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental meditation
Description: The TM technique was taught as a standard 7 step course over 4 consecutive days. Thereafter, subjects attended bimonthly group meetings for more advanced knowledge over the four month intervention period.
Study: NCT02036359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: 150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.
Study: NCT03370016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amount of Pneumoperitoneum Pressure applied during RARP
Description: Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 8 mmHg (experimental) or 12mm Hg (standard technique)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amount of Pneumoperitoneum Pressure applied during RARP
Description: Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 8 mmHg (experimental) or 12mm Hg (standard technique)
Study: NCT00439270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.
Study: NCT06337058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group (motivational interview)
Description: For the menopausal women with sexual dysfunction in the experimental group, pre-test data were obtained by applying the 'Personal Information Form', the 'Sexual Quality of Life Scale-Woman' and the 'Sexual Self-Efficacy Scale' before starting the motivational interviews. After the pre-test data were obtained, a total of 4 sessions of motivational interviews were provided, one session per week for four weeks. At the end of four weeks, post-test data were obtained by applying the Arizona Sexual Experiences Scale, Sexual Quality of Life Scale-Women and Sexual Self-Efficacy Scale.~The researcher received a training on motivational interview techniques before implementing the intervention for menopausal women in the experimental group.
Study: NCT01898585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zelboraf
Description: Vemurafenib 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.
Study: NCT01170468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 5000 IU orally, daily for 2 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally, daily for 2 years
Study: NCT04044313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks
Study: NCT00383266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT01578460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: Participants in the CGM group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using the iPro2 CGM.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Meter
Description: Participants in the control group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using a glucose meter.
Study: NCT03775655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 10μg dexmedetomidine will be added to the injectate to be injected intrathecally
Study: NCT03393637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentors Offering Maternal Support (M-O-M-S)
Description: 10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
Study: NCT04160195

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
Description: Dose-escalation trial starting dose: 0.66 x10\^6 CAR+ T cells/kg (weight-based dosing one time) (up to a maximum dose of 10x10\^6 CAR+ T cells/kg based on cohort) infuse on day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
Description: Dose-escalation trial starting dose: 0.66 x10\^6 CAR+ T cells/kg (weight-based dosing one time) (up to a maximum dose of 10x10\^6 CAR+ T cells/kg based on cohort) infuse on day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
Study: NCT01211327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Cyclosporine 2% eye drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 0,1% eye drops
Study: NCT03633695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IC-8 IOL Group
Description: A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) implanted in the first eye for use over the lifetime of the patient. The IC-8 IOL implanted in the second eye for use over the lifetime of the patient.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) bilaterally implanted for lifetime use of the patient.
Study: NCT01415284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch 130/0.4
Description: first patient : 500 mL. Following volumes according to up-down sequential allocation, with increments or decrements of 100 mL. An absence of hypotension will lead to an decrement while a presence of hypotension will result in an increment.
Study: NCT02430311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablet-150mg, Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablet-100mg, Oral
Study: NCT01906502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensimed Triggerfish
Study: NCT01512277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rSh28GST
Description: subcutaneous route at Day 0, Day 28, and Day 150 for the third administration of 100µg for Arm 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rSh28GST
Description: subcutaneous route at Day 0, Day 28, and Day 150 for the third administration of 100µg for Arm 1

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rSh28GST
Description: subcutaneous route at Day 0, Day 28, and Day 150 for the third administration of 100µg for Arm 1
Study: NCT01144286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arasertaconazole nitrate
Description: Arasertaconazole nitrate pessary, placebo pessary

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arasertaconazole nitrate
Description: Arasertaconazole nitrate pessary, placebo pessary
Study: NCT01223690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5%
Description: 1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days